Oxford Cancer Analytics (OXcan) is a medtech company developing protein-based blood tests for early cancer detection using advanced proteomics, explainable machine learning, and AI. Its core product is a protein-based liquid biopsy intended to identify molecular signatures in high-risk lung cancer patients with high accuracy and localization capacity. OXcan leverages a diverse global biobank and, since 2023, has partnered with over 20 healthcare centers across three continents to develop and deploy its technology. The company has achieved ISO13485 certification and describes the test as affordable, minimally invasive, and suitable for routine population screening. OXcan plans to use new funding to develop and globally commercialize its next-generation lung cancer blood tests. It recently raised US$11 million in a Series A and appointed Dr. Heinrich Roder as Senior Vice President of R&D to advance its lung cancer blood test toward deployment.

Total raised

$11M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025